Melanoma Matters

Summary

James gives a response of plausible deniability that hints at activities as a spy for MI6. But is Sapna perhaps the optimal agent for the clandestine services?

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss the intricacies of the MASTERKEY 265 study, focusing on the combination of TVEC and pembrolizumab in melanoma treatment. They explore the study's design, patient demographics, and the implications of geographical variations on trial outcomes. The conversation highlights the importance of understanding patient selection and trial design in oncology, as well as the lessons learned from the study's overall negative results.

Keywords

TVEC, Master Key 265, melanoma, immunotherapy, clinical trials, patient demographics, efficacy, safety, geographical variations, oncology

Takeaways

The Master Key 265 study had dual primary endpoints of PFS and OS.

TVEC was combined with Pembrolizumab in the study.

The phase 1B trial showed significant efficacy but the phase 3 trial was negative.

Patient demographics can greatly influence trial outcomes.

Geographical variations can lead to different efficacy results.

Toxicity levels were similar between the treatment arms.

The study design must consider patient selection carefully.

The Optim study had different eligibility criteria than Master Key 265.

Understanding baseline characteristics is crucial for interpreting trial results.

Future trials should learn from the design of Master Key 265.

Titles

Lessons Learned from Master Key 265

The Role of Trial Design in Oncology

Sound Bites

"This was an interesting study because it was a phase 1B."

"The toxicity between the two arms was really exceptionally similar."

Chapters

00:00 Combining Intratumoral Therapies with Checkpoint Inhibitors

04:51 Master Key 265 Study: TVEC and Pembrolizumab Combination

09:42 Primary Endpoint: Progression-Free Survival

11:44 Importance of Durable Response Rate as an Endpoint

13:37 Limited Activity of TVEC and Pembrolizumab Combination

14:52 Geographical Variation in Treatment Outcomes

Summary

One wonders if Prof Martin Gore ever dreamed he would be mentioned in the same context as HRH and Taylor Swift. If he's listening, he must know which of the goldilocks chairs he occupies.

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss injectable therapies for melanoma, focusing on Talimogene Laherparepvec (TVEC) and the Optim trial. They explore the trial's design, patient selection criteria, and practical considerations for administering TVEC in clinical settings. The conversation also touches on the implications of patient characteristics and treatment history on the effectiveness of TVEC, as well as future directions for combination therapies in melanoma treatment.

Keywords

melanoma, Talimogene Laherparepvec, TVEC, injectable therapy, Optim trial, cancer treatment, oncolytic virus, patient selection, clinical trials, immunotherapy

Takeaways

Talimogene Laherparepvec (TVEC) is the only approved oncolytic viral therapy for melanoma.

The Optim trial demonstrated the efficacy of TVEC compared to GMCSF.

Patient selection is crucial for the success of TVEC treatment.

Injectable therapies are often used for patients with low visceral disease.

Size and volume of tumors significantly impact the effectiveness of TVEC injections.

The control arm of the Optim trial was not a standard therapy.

TVEC administration requires careful consideration of tumor characteristics.

Combination therapies may enhance the effectiveness of TVEC.

Understanding patient history is important for treatment decisions.

Future research may lead to more approvals in the field of oncolytic therapies.

Chapters

00:00 Introduction and Rapid Fire Questions

03:52 Overview of the Optim Trial

10:09 Practical Considerations for Using T-VEC in Clinic

14:15 Patient Selection for T-VEC Therapy

16:23 Dosing and Injection Techniques for T-VEC

Summary

In this episode of Melanoma Matters, Sapna Patel and James Larkin discuss the IMMUNED study, a randomized phase 2 trial for resected stage 4 melanoma with no evidence of disease (NED). They explore the study design, efficacy results, and subgroups analysis. They also discuss the use of checkpoint inhibitors in the adjuvant setting and the management of oligometastatic disease. The key takeaway is that anti-PD-1 monotherapy is likely under treatment for stage 4 NED, but the approach may vary depending on individual patient factors and reimbursement limitations.

Keywords

Melanoma, IMMUNED study, stage 4 NED, checkpoint inhibitors, adjuvant therapy, oligometastatic disease

Takeaways

Sound Bites

"Anti-PD-1 monotherapy is probably under treatment for stage 4 NED."

"The BRAF mutation status is consistent with what we saw in Checkmate 67."

"The management of oligometastatic disease requires individualized approaches."

Chapters

00:00 Introduction and Childhood Jobs

04:03 Overview of the IMMUNED Study

07:51 Efficacy and Forest Plots

10:47 Utilizing the IMMUNED Study in the Clinic

14:29 Subgroup Analysis and BRAF Status

21:11 Treatment Algorithms for Stage IV NED

26:46 Managing Oligometastatic Disease

30:54 No Easy Answers and Controversial Questions

34:10 Personalized Treatment and Reimbursement Limitations

Summary

In this conversation, James Larkin and Sapna Patel discuss the S1801 study, a neoadjuvant study in melanoma. They talk about the background and design of the study, including the decision to compare neoadjuvant therapy to adjuvant therapy using pembrolizumab. They also discuss the efficacy and toxicity of the neoadjuvant approach, as well as the importance of central pathologic review. They mention the NADINA study as the next step in exploring combination therapy in the neoadjuvant setting.

Keywords

neoadjuvant therapy, melanoma, S1801 study, pembrolizumab, adjuvant therapy, efficacy, toxicity, central pathologic review, NADINA study

Takeaways

Sound Bites

"The group that took neoadjuvant-adjuvant had a statistically significant improvement in event-free survival."

"Once we did central review, the pathologic (complete) response nearly doubled."

"The NADINA study will tell us if combination therapy in the neoadjuvant setting is highly effective."

Chapters

00:00 Introduction and Background of S1801 Study

07:19 Study Design and Endpoints

13:33 Efficacy and Toxicity Insights

Summary

In this conversation, James Larkin and Sapna Patel discuss the PRADO study, which focuses on neoadjuvant therapy for melanoma. The study explores the use of personalized response-driven approaches to treatment, based on the patient's response to combination immunotherapy. The study found that patients with a major pathological response had a low rate of recurrence in the first two years, suggesting a favorable outcome. However, there were still some patients who experienced recurrence, particularly those with multiple clinically positive lymph nodes. The discussion also touches on the challenges of defining and categorizing pathological response and the importance of accurate sampling and analysis.

Keywords

PRADO, neoadjuvant therapy, melanoma, personalized response-driven approach, major pathological response, recurrence, lymph nodes, sampling, analysis

Takeaways

Sound Bites

"Patients with a major pathological response had an excellent response."

"Patients with multiple clinically positive lymph nodes may require additional surgery."

"The definition of pathological response is not uniform across tumor types."

Chapters

00:00 Introduction and Favorite Recording Artists

02:30 Background and Importance of the Prado Study

07:00 Categorizing Pathological Responses and Cherry Picking Lymph Nodes

08:38 Hypotheses and Outcomes for Major Pathologic Response

11:42 Setting Cutoffs and the Role of Sampling in Pathology

23:42 Global Impact of the PRADO Study and the Need for Adjuvant Therapy

Summary

In this conversation, James Larkin and Sapna Patel discuss neoadjuvant treatment in melanoma. They start by talking about the best films they've seen in the last five years, then move on to the background and rationale behind neoadjuvant therapy. They discuss the use of BRAF targeted therapy and its limitations, as well as the effectiveness of immunotherapy in the neoadjuvant setting. They also touch on the importance of biomarkers and the potential for reducing surgery and adjuvant therapy in the future. The conversation highlights the OPACIN neo study and its findings, as well as the need for further research in this area.

Keywords

neoadjuvant treatment, melanoma, BRAF targeted therapy, immunotherapy, biomarkers, surgery, adjuvant therapy, OPACIN neo

Takeaways

Sound Bites

"The education you get while the tumor is clearly visible is stronger than the education the immune system would get if you removed it and then it was fighting microscopic cancer."

"Immunotherapy gives you immunological memory that continues after you take the drug away."

"The patients who got neoadjuvant therapy had a more amplified and a more diverse immune system."

Chapters

00:00 Introduction and Film Discussion

02:30 The Background of Neoadjuvant Treatment

03:50 Neoadjuvant Treatment with BRAF Targeted Therapy

07:26 The Promise of Immunotherapy in Neoadjuvant Treatment

08:33 The OPACINeo Study and Biomarkers

19:03 Conclusion

Summary

Birth order and bad second languages and Bolivia. In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss the Checkmate 915 trial, a significant study in the adjuvant treatment of melanoma. They explore the trial's design, the implications of IPI dosing, and the balance between efficacy and toxicity. The conversation emphasizes the importance of understanding negative studies in clinical research and the need for careful consideration in trial design, particularly in the adjuvant setting.

Keywords

Checkmate 915, melanoma, adjuvant therapy, IPI dosing, trial design, toxicity, efficacy, negative studies, immunotherapy, clinical trials

Takeaways

Checkmate 915 was a large adjuvant trial in melanoma.

The trial compared Nivolumab monotherapy to Nivolumab with low-dose IPI.

There was no improvement in relapse-free survival with the addition of IPI.

Toxicity was higher in the IPI-containing arm, as expected.

The dosing of IPI in Checkmate 915 was significantly lower than in metastatic settings.

Understanding the trade-off between efficacy and toxicity is crucial in adjuvant therapy.

Negative studies are important for learning and future trial designs.

The design of Checkmate 915 was pragmatic given the context of adjuvant treatment.

Future research may benefit from exploring neoadjuvant models.

The conversation highlights the need for more discussions on negative trials.

Titles

Checkmate 915: What Went Wrong?

Understanding Checkmate 915: A Deep Dive

Sound Bites

"This was an important large study in our field."

"The addition of this low dose IPI regimen did not improve relapse free survival."

"We need to try and think more and talk more about why studies are negative."

Chapters

00:00 Introduction and Quick Fire Questions

02:50 Discussion of Checkmate 915 Study

11:02 The Dosing Dilemma: Ipilimumab in the Adjuvant Setting

15:41 Takeaways from Checkmate 915 Study

Summary

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin have a disastrous quickfire discussing their would-be porn star names and eventually move on to the Checkmate 76K study, which evaluates the efficacy of Nivolumab in adjuvant therapy for stage 2 melanoma. They delve into the interpretation of hazard ratios, the choice between Nivolumab and Pembrolizumab, and the management of toxicities associated with these treatments. The conversation also touches on the future of subcutaneous formulations and their potential impact on patient care. Key takeaways highlight the importance of monitoring and the implications of insurance on treatment decisions.

Keywords

melanoma, adjuvant therapy, Checkmate 76K, Nivolumab, Pembrolizumab, hazard ratio, toxicity management, subcutaneous formulations

Takeaways

Checkmate 76K shows clear benefit in relapse-free survival.

Nivolumab and Pembrolizumab are both viable options.

Hazard ratios can be misinterpreted; context is crucial.

Pragmatism and reimbursement influence treatment choices.

Regular monitoring is essential for managing toxicities.

Subcutaneous formulations may improve patient convenience.

Early nephritis is a significant concern in treatment.

Insurance issues can complicate treatment decisions.

Data from Checkmate 76K aligns with Keynote 716 findings.

Patient safety should always be prioritized in therapy.

Sound Bites

"Checkmate 76K shows clear benefit in RFS."

"Nivolumab versus Pembrolizumab, both are options."

"Managing toxicities is crucial in adjuvant therapy."

Chapters

00:00 Introduction and Rapid Fire Questions

02:33 Overview of Checkmate 76K Study

05:08 Choosing between Nivolumab and Pembrolizumab

13:11 Potential of Subcutaneous Formulations

15:25 Summary and Conclusion

Summary

In this episode of Melanoma Matters, James Larkin and Sapna Patel discuss the Keynote 716 trial, focusing on the treatment of stage 2 melanoma. They explore the implications of adjuvant therapies, the significance of recurrence-free survival (RFS) and distant metastasis-free survival (DMFS), and the role of BRAF testing in managing stage 2 patients. The conversation highlights the challenges in treating early-stage melanoma and the need for accurate biomarkers to identify high-risk patients. The episode concludes with reflections on the findings of Keynote 716 and future directions in melanoma treatment.

Keywords

melanoma, Keynote 716, stage 2 melanoma, adjuvant treatment, BRAF testing, recurrence-free survival, distant metastasis-free survival, immunotherapy, targeted therapy, clinical trials

Takeaways

Keynote 716 focuses on adjuvant treatment for stage 2 melanoma.

The trial shows benefit for pembrolizumab in stage 2B and 2C.

There are challenges in treating early-stage melanoma effectively.

The hazard ratio for pembrolizumab is around 0.6 for stage 2.

Accurate biomarkers are needed for early-stage melanoma.

The majority of melanoma patients are diagnosed at stage 1 or 2.

Local and regional recurrences are concerning for patients.

The conversation around treatment options continues to evolve.

Titles

Keynote 716: A New Era for Stage 2 Melanoma

The Challenges of Treating Early-Stage Melanoma

Sound Bites

"This is basically adjuvant treatment for stage 2 melanoma."

"Keynote 716 was a randomized phase three trial."

"DMFS is really our most relevant endpoint for adjuvant trials."

Chapters

00:00 Introduction

02:38 Quickfire Questions and Introduction to Keynote 716

04:31 Keynote 716 Trial Design and Results

06:41 Interpreting DMFS and Regional Recurrence

08:40 Overlap Between Stage Two and Stage Three

10:58 Exploring Combination Therapy for Recurrence

13:15 Testing for BRAF Mutations in Stage Two

17:00 Reimbursement and Timing of Mutational Testing

22:18 Reimbursement Issues and Quick Results for Mutational Testing

25:00 Summary and Closing Remarks

Summary

James is injured! Hear about his favorite style of exercise (strength v cardio), and his no excuses attitude towards aches, pains, and niggles.

In this episode, Sapna and James discuss the Keynote 054 study, which examines the efficacy of adjuvant pembrolizumab (Pembro) versus placebo in patients with resected stage 3A to 3C melanoma. They explore the study's design, results, and implications for treatment decisions, particularly regarding toxicity management and the challenges of interpreting crossover designs. The discussion also touches on the significance of endocrine side effects and the importance of using minimal immunosuppression to maintain treatment efficacy.

Keywords

melanoma, adjuvant therapy, Keynote 054, toxicity management, immune activation, treatment decisions, PD-1 therapy, melanoma research, cancer treatment, clinical trials

Takeaways

Adjuvant Pembro shows significant RFS benefit compared to placebo.

Crossover design complicates treatment decisions in clinical practice.

Toxicity management is crucial for patient safety and treatment efficacy.

Endocrine side effects may indicate immune activation and treatment sensitivity.

Minimal immunosuppression is recommended to avoid blunting treatment effects.

The hazard ratio for benefit is similar across melanoma stages.

Real-world treatment decisions often deviate from trial protocols.

Understanding toxicity trends is essential for effective management.

Patients with endocrine side effects may not require high-dose steroids.

Keynote 054 highlights the need for careful interpretation of adjuvant therapy results.

Sound Bites

"Adjuvant Pembro for a year versus placebo."

"Significant RFS benefit in comparison with placebo."

"The now or later question is inevitable."

Chapters

00:00 Introduction and Quick Fire Questions

03:25 Keynote 054: Adjuvant Pembrolizumab in Stage 3 Melanoma

10:48 Managing Toxicity in the Adjuvant Setting